Detail akcie Profound Medicl Rg online

Business Summary: Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Profound Medical Corp revenues increased 32% to $4.8M. Net loss increased 96% to $26.4M. Revenues reflect USA segment increase of 56% to $3.5M. Higher net loss reflects Selling, general and administrative increase of 78% to $17.5M (expense), Total other (income) expenses decrease from $1.4M (income) to $2.1M (expense).